Research abuses against people of colour and other vulnerable groups in early psychedelic research
This review of early psychedelic studies (the 50s-70s, s=48) finds that most (77%) would not pass ethical review today. The errors made in early research were extensive dosing, lack of consent, inadequate setting, and lack of scientific hypotheses. The authors make restorative justice and cultural competency suggestions.
Authors
- Thomas Williams
- Monnica Williams
- Jordan Sloshower
Published
Abstract
There is a growing resurgence in the study of psychedelic medicines for the treatment of mental health and substance use disorders. However, certain early investigations are marred by questionable research methods, abuses against research participants, and covert Central Intelligence Agency financial involvement. The purpose of this study was to understand how and to what extent people of colour and other vulnerable populations, specifically, individuals who were incarcerated or incapacitated due to mental health issues (inpatients with psychotic disorders), were exploited during the first wave of psychedelic research in the USA (1950-1980). To do so, we reviewed available empirical publications according to current ethical standards. Variables of interest included race and ethnicity of participants, population vulnerability, drug administration conditions, informed consent and undue influence. Our findings draw attention to the history of research abuses against people of colour in Western psychedelic research. In light of these findings, we urge a call-to-action to current psychedelic researchers to prioritise culturally inclusive and socially responsible research methods in current and future studies.
Research Summary of 'Research abuses against people of colour and other vulnerable groups in early psychedelic research'
Introduction
Schultes and colleagues situate this work within the "first wave" of Western psychedelic research in the USA (approximately 1950–1980), a period of intense investigation of substances such as LSD, psilocybin, DMT and mescaline for psychiatric indications and other experimental uses. The introduction summarises how early enthusiasm for therapeutic applications coincided with Cold War research programmes (notably CIA-funded MKUltra) and with broader historical currents that shaped research practices and participant selection. The authors highlight that ethical safeguards such as the Nuremberg Code, the Declaration of Helsinki and, later, the Belmont Report emerged contemporaneously or subsequently, yet many early studies appear to have disregarded these principles, particularly with respect to vulnerable groups including people of colour (POC), incarcerated people and psychiatric inpatients. This investigation aims to document how and to what extent POC and other vulnerable populations were unduly exploited in early US psychedelic research. The study addresses recruitment strategies, study methodologies and safety practices in human trials from 1950–1980, with a focus on whether participants were drawn from marginalised ethnic/racial groups, lacked decisional capacity, or were incarcerated. By reviewing primary publications and historical sources, the authors seek to contextualise modern underrepresentation of POC in contemporary psychedelic research and to suggest avenues for redress and culturally competent practice going forward.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Strauss, D., de la Salle, S., Sloshower, J., & Williams, M. T. (2022). Research abuses against people of colour and other vulnerable groups in early psychedelic research. Journal of Medical Ethics, 48(10), 728-737. https://doi.org/10.1136/medethics-2021-107262
References (14)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Belouin, S. J., Henningfield, J. E. · Neuropharmacology (2018)
Fuentes, J. J., Fonseca, F., Elices, M. et al. · Frontiers in Psychiatry (2020)
Bonson, K. R. · Psychopharmacology (2017)
Nichols, D. E. · Pharmacological Reviews (2016)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)
Osmond, H. · Annals of the New York Academy of Sciences (2010)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Show all 14 referencesShow fewer
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Tomsovic, M., Edwards, R. V. · Journal of Studies on Alcohol and Drugs (1970)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Williams, M. T., Reed, S., George, J. · Journal of Psychedelic Studies (2021)
Cited By (4)
Papers in Blossom that reference this study
Torre, J. T. L., Gallo, J., Mahammadli, M. et al. · Journal of Psychedelic Studies (2024)
La Torre, J. T., Mahammadli, M., Faber, S. et al. · International Journal of Mental Health and Addiction (2023)
La Torre, J. T., Mahammadli, M., Greenway, K. T. et al. · BMC Psychiatry (2022)
Smith, D., Faber, S., Buchanan, N. T. et al. · Frontiers in Psychiatry (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.